BEAM NASDAQ
Beam Therapeutics Inc.
1W: -6.3%
1M: -12.7%
3M: +0.3%
YTD: +1.9%
1Y: +55.9%
3Y: -18.3%
5Y: -61.5%
$28.64
+0.97 (+3.51%)
Weekly Expected Move ±11.5%
$21
$25
$28
$31
$34
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Abu Dhabi expo puts Beam's off-grid EV chargers before UAE buyers - Stock Titan
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure
Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Yahoo Finance
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress - simplywall.st
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Yahoo Finance
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”
Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
12 Stocks to Buy After Meta’s Deal to Beam Energy From Space - InvestorPlace
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
Why Beam Therapeutics Stock Is Sliding Again - TipRanks
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
BEAM Forecast, Price Target & Analyst Ratings | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed?
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed? - Yahoo Finance
Three Best Genomics Stocks for Your Portfolio in 2026
Beam Therapeutics Stock Rockets After Breakthrough Data - TipRanks
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - The Motley Fool
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares
Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares
Beam Therapeutics (NASDAQ:BEAM) CEO John Evans Sells 30,078 Shares
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Why is BEAM stock edging higher after hours today? - MSN
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM
John Evans Sells 25,000 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years - Yahoo Finance
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics CEO Evans sells $1.1m in stock - Investing.com
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding
How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Shares Up 5.5% After Analyst Upgrade
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics stock jumps on positive trial data - Investing.com
Beam Therapeutics Inc. $BEAM Position Increased by Hudson Bay Capital Management LP
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - Yahoo Finance
Q1 EPS Forecast for Beam Therapeutics Lowered by Analyst
ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM
Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM
What is HC Wainwright’s Forecast for BEAM Q1 Earnings?
Cathie Wood's weekly recap: adds defense stock Kratos, CoreWeave, Baidu
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why
Beam Therapeutics: Great Potential, But Patience Is Needed
Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics Stock Surges 14% on Strategic Financing: How the $500M Agreement Secures a $156 Target - TIKR.com
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary
Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: Strategic Financing and ...
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Beam Therapeutics Q4 Earnings Call Highlights
What's Going On With Beam Therapeutics Stock?
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
Beam Therapeutics GAAP EPS of $2.33, revenue of $114.1M
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
BofA raises Beam Therapeutics stock price target on pipeline progress - Investing.com
$BEAM stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
Beam Global (BEEM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 18,629 Shares of Stock
SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment - Investing.com
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics: Pivoting From Platform To Execution Stage
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Zacks Investment Research
Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing Plan
Bernstein raises Beam Therapeutics stock price target to $37 on AATD program outlook - Investing.com
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition